Stockscreener 앱 받기
822.51
0.27%
-2.25
시간 외 거래:
822.00
-0.51
-0.06%
전일 마감가:
$824.76
열려 있는:
$833.42
하루 거래량:
2.27M
Relative Volume:
0.68
시가총액:
$738.75B
수익:
$45.04B
순이익/손실:
$10.59B
주가수익비율:
70.24
EPS:
11.71
순현금흐름:
$414.30M
1주 성능:
-0.19%
1개월 성능:
-4.05%
6개월 성능:
-9.11%
1년 성능:
+7.85%
1일 변동 폭
$812.62
$836.29
1주일 범위
$795.38
$836.29
52주 변동 폭
$711.40
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
213.85 | 377.52B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
80.98 | 359.47B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
164.25 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.72 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Eli Lilly And Company (LLY): Among Stocks to Buy That May Be Splitting Soon - Insider Monkey
Is Eli Lilly and Company (LLY) the Best Diabetes Stock to Buy According to Billionaires? - Insider Monkey
Eli Lilly’s $3B Expansion Gets Green Light in Kenosha County - Civic Media
Eli Lilly stock holds strong on Outperform rating by Bernstein - Investing.com
Jim Cramer Says Eli Lilly And Co (LLY) Sellers Are ‘Uninformed’ - Insider Monkey
Eli Lilly wins final approval for $3B expansion in Pleasant Prairie - The Business Journals
Eli Lilly, Pfizer Back Teva Fight of US Drug Price Negotiations - Bloomberg Law
Eli Lilly: A Safe Harbor Amid Market Volatility (NYSE:LLY) - Seeking Alpha
Positive Outlook for Eli Lilly & Co. Amid FDA Support and Strong Revenue Projections - TipRanks
Citi sees positive read-through to Lilly shares on FDA GLP-1 statement - TipRanks
This Is What Whales Are Betting On Eli Lilly - Benzinga
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation - The Motley Fool
Pharmaceutical Giants Like J&J, Merck, and Eli Lilly Accelerate - openPR
How Eli Lilly is Shaping Kinsale and Ireland's Economic LandscapeNews and Statistics - IndexBox, Inc.
Is Eli Lilly and Company (LLY) the Best Quality Stock to Invest in Now? - MSN
Jim Cramer Says: “Keep an Eye on Eli Lilly and Company (LLY)” - Insider Monkey
Slow NHS puts investment at risk, warns ‘King Kong’ weight-loss jab maker - The Telegraph
Tesla's problems, Eli Lilly's weight loss pill, and egg prices surge: Business news roundup - Yahoo Finance
Eli Lilly snaps six days of losses - Seeking Alpha
Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily
Senators expand probe of Pfizer, Lilly DTC platforms to include telehealth provider partners - FiercePharma
Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly - STAT
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk (NYSE:ABBV) - Seeking Alpha
Eli Lilly’s SVP Donald Zakrowski sells $818,240 in stock - Investing.com
Eli Lilly’s Promising Position in Weight Management Market Drives Buy Rating - TipRanks
Lilly, J&J boosted spending on executive security after UnitedHealth shooting - MSN
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer - STAT
Durbin, Warren, Welch, Sanders Demand Answers From Telehealth Companies Regarding Their Financial Relationship With Pfizer, Eli Lilly Amid Concerns - RiverBender.com
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly - Investopedia
Lilly CEO got a big payday (and an Olympics treat) - STAT
Eli Lilly Suit Over Compounded Drugs Survives Dismissal - Law360
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes - STAT
Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025? - Insider Monkey
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss - AOL
Unpacking the Latest Options Trading Trends in Eli Lilly - Benzinga
Eli Lilly & Co: Promising CagriSema Performance Justifies Buy Rating Despite Tolerability Concerns - TipRanks
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock? - Nasdaq
Is Eli Lilly Stock a Buy? - The Motley Fool
Why Eli Lilly Stock Flopped Today - The Motley Fool
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. - Investor's Business Daily
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says - Yahoo Finance
Lilly sees launching weight loss drugs in China, India starting late 2025 - Seeking Alpha
Judge Denies Injunction for Copycats of Lilly's Weight Loss Drug - Bloomberg Law
Eli Lilly plans to launch weight-loss drug in emerging markets this year - Reuters
Eli Lilly to debut weight loss drug in China, India - baha news
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says - Bilyonaryo Business News
Morgan Stanley maintains Eli Lilly Overweight rating, $1,146 target By Investing.com - Investing.com South Africa
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says - Marketscreener.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
1.04%
자본화:
|
볼륨(24시간):